Pivotal bioVenture Partners led a $145m Series B financing round in Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The financing round saw investments from Viking Global Investors, TPG’s The Rise Fund, F-Prime Capital, funds managed by Tekla Capital Management, Solasta Ventures, Fairview Capital, and Mitsui & Co, 5AM Ventures, Canaan Partners, New Leaf Venture Partners and Connecticut Innovations. “The Rallybio team is highly motivated to bring our innovative product candidates to patients suffering from devastating rare disorders. With ambitious plans to progress our current pipeline, expand our portfolio, and grow our team of rare disease experts, we appreciate the profound support of our knowledgeable and esteemed investors,” Martin Mackay, Rallybio Chairman and CEO.